[go: up one dir, main page]

WO2011044230A9 - N-acétylcystéine amide (nac amide) destiné au traitement de maladies et de conditions - Google Patents

N-acétylcystéine amide (nac amide) destiné au traitement de maladies et de conditions Download PDF

Info

Publication number
WO2011044230A9
WO2011044230A9 PCT/US2010/051623 US2010051623W WO2011044230A9 WO 2011044230 A9 WO2011044230 A9 WO 2011044230A9 US 2010051623 W US2010051623 W US 2010051623W WO 2011044230 A9 WO2011044230 A9 WO 2011044230A9
Authority
WO
WIPO (PCT)
Prior art keywords
amide
diseases
treatment
conditions
acetylcysteine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2010/051623
Other languages
English (en)
Other versions
WO2011044230A2 (fr
Inventor
Glenn A. Goldstein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of WO2011044230A2 publication Critical patent/WO2011044230A2/fr
Publication of WO2011044230A9 publication Critical patent/WO2011044230A9/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PCT/US2010/051623 2009-10-06 2010-10-06 N-acétylcystéine amide (nac amide) destiné au traitement de maladies et de conditions Ceased WO2011044230A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US24912209P 2009-10-06 2009-10-06
US61/249,122 2009-10-06
US25180209P 2009-10-15 2009-10-15
US61/251,802 2009-10-15

Publications (2)

Publication Number Publication Date
WO2011044230A2 WO2011044230A2 (fr) 2011-04-14
WO2011044230A9 true WO2011044230A9 (fr) 2011-08-18

Family

ID=43857367

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/051623 Ceased WO2011044230A2 (fr) 2009-10-06 2010-10-06 N-acétylcystéine amide (nac amide) destiné au traitement de maladies et de conditions

Country Status (1)

Country Link
WO (1) WO2011044230A2 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10201513B2 (en) 2016-12-19 2019-02-12 Axcella Health Inc. Amino acid compositions and methods for the treatment of liver diseases
US10596136B2 (en) 2018-06-20 2020-03-24 Axcella Health Inc. Compositions and methods for the treatment of fat infiltration in muscle
US10660870B2 (en) 2017-08-14 2020-05-26 Axcella Health Inc. Compositions and methods for the treatment of liver diseases and disorders associated with one or both of hyperammonemia or muscle wasting

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013175479A1 (fr) 2012-05-24 2013-11-28 Hadasit Medical Research Services And Development Ltd. Compositions comprenant de l'isosilybine b pour l'amélioration et la prévention de la toxicité induite par un médicament
CN103070294A (zh) * 2013-01-31 2013-05-01 武汉工业学院 N-乙酰半胱氨酰胺作为饲料添加剂的应用
EP3019164B1 (fr) * 2013-07-10 2020-08-19 Glenn A. Goldstein Emploi de n-acétylcystéine amide dans le traitement de lésions profondes à la tête
WO2015112715A1 (fr) * 2014-01-24 2015-07-30 Brighton Biotech, Inc. Naca pour le traitement d'un traumatisme cérébral à faible impact ou chronique
US20150209309A1 (en) * 2014-01-24 2015-07-30 Brighton Biotech, Inc Naca for the treatment of chronic or acute cognitive dysfunction
RU2711913C2 (ru) 2014-11-07 2020-01-24 Дзе Джонс Хопкинс Юниверсити Лечение пигментной дистрофии сетчатки n-ацетилцистеинамидом
WO2016197089A1 (fr) * 2015-06-05 2016-12-08 Goldstein Glenn A Utilisation de n-acétylcystéine amide dans le traitement d'une surdose d'acétaminophène
US20190135741A1 (en) 2017-11-09 2019-05-09 Nacuity Pharmaceuticals, Inc. Methods of Making Deuterium-Enriched N-acetylcysteine Amide (D-NACA) and (2R, 2R')-3,3'-Disulfanediyl BIS(2-Acetamidopropanamide) (DINACA) and Using D-NACA and DINACA to Treat Diseases Involving Oxidative Stress
US12245998B2 (en) 2019-01-11 2025-03-11 Nacuity Pharmaceuticals, Inc. N-acetylcysteine amide (NACA) and (2R,2R′)-3,3′ disulfanediyl bis(2-acetamidopropanamide) (diNACA) for the prevention and treatment of radiation pneumonitis and treatment of pulmonary function in Cystic Fibrosis
US11766413B2 (en) * 2019-01-11 2023-09-26 Nacuity Pharmaceuticals, Inc. Treatment of age-related macular degeneration, glaucoma, and diabetic retinopathy with n-acetylcysteine amide (NACA) or (2R,2R′)-3,3′-disulfanediyl BIS(2-acetamidopropanamide)(DiNACA)
US12458608B2 (en) * 2019-01-11 2025-11-04 Nacuity Pharmaceuticals, Inc. N-Acetylcysteine Amide (NACA) and (2R,2R′)-3,3′ disulfanediyl BIS(2-acetamidopropanamide) (DINACA) for the prevention and treatment of radiation dermatitis and skin lightening, skin whitening and skin improvement
CN116075322A (zh) * 2020-04-24 2023-05-05 阿什瓦塔治疗股份有限公司 用于治疗重度急性呼吸窘迫综合征的树枝状大分子组合物和方法
WO2021217221A1 (fr) * 2020-05-01 2021-11-04 MUCPharm Pty Ltd Prévention et traitement d'infections virales
US11911178B2 (en) 2020-05-05 2024-02-27 Northwestern University System and method to detect and treat arrhythmogenic regions in atrial fibrillation
NL2025679B1 (en) * 2020-05-26 2021-12-13 Johanna Daams Brechtje Electrical stimulation for preventing or treating nitric oxide deficiency related conditions
GB202301355D0 (en) * 2023-01-31 2023-03-15 Univ London Queen Mary Use

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10201513B2 (en) 2016-12-19 2019-02-12 Axcella Health Inc. Amino acid compositions and methods for the treatment of liver diseases
US10238617B2 (en) 2016-12-19 2019-03-26 Axcella Health Inc. Amino acid compositions and methods for the treatment of liver diseases
US10471034B2 (en) 2016-12-19 2019-11-12 Axcella Health Inc. Amino acid compositions and methods for the treatment of liver diseases
US11129804B2 (en) 2016-12-19 2021-09-28 Axcella Health Inc. Amino acid compositions and methods for the treatment of liver diseases
US11602511B2 (en) 2016-12-19 2023-03-14 Axcella Health Inc. Amino acid compositions and methods for the treatment of liver diseases
US10660870B2 (en) 2017-08-14 2020-05-26 Axcella Health Inc. Compositions and methods for the treatment of liver diseases and disorders associated with one or both of hyperammonemia or muscle wasting
US10682325B2 (en) 2017-08-14 2020-06-16 Axcella Health Inc. Compositions and methods for the treatment of liver diseases and disorders associated with one or both of hyperammonemia or muscle wasting
US11571404B2 (en) 2017-08-14 2023-02-07 Axcella Health Inc. Compositions and methods for the treatment of liver diseases and disorders associated with one or both of hyperammonemia or muscle wasting
US10596136B2 (en) 2018-06-20 2020-03-24 Axcella Health Inc. Compositions and methods for the treatment of fat infiltration in muscle
US10973793B2 (en) 2018-06-20 2021-04-13 Axcella Health Inc. Compositions and methods for the treatment of fat infiltration in muscle
US11833127B2 (en) 2018-06-20 2023-12-05 Axcella Health Inc. Compositions and methods for the treatment of fat infiltration in muscle

Also Published As

Publication number Publication date
WO2011044230A2 (fr) 2011-04-14

Similar Documents

Publication Publication Date Title
WO2011044230A9 (fr) N-acétylcystéine amide (nac amide) destiné au traitement de maladies et de conditions
IL186684A0 (en) N-acetylcysteine amide (nac amide) for the treatment of diseases and conditions associated with oxidative stress
AP3069A (en) Thienopyridine derivatives for the treatment and prvention of dengue virus infection
IL193473A0 (en) Amide derivatives and their application for the treatment of g protein related diseases
SI2440550T1 (sl) Indolamidni derivati in povezane spojine za uporabo pri zdravljenju neurodegenerativnih bolezni
IL216618A0 (en) Novel compound useful for the treatment of degenerative and inflammatory diseases
IL216967B (en) The history of 17-hydroxy-17-pentafluoroethyl-astra-9,4 (10)-diene-11-aryl and their use for the treatment of diseases
GB2458868A8 (en) Treatment of protein aggregation diseases
IL213703A (en) Compounds for the treatment of pain and other diseases
IL223219A0 (en) Flufenoxine derivatives for the treatment and prevention of amiloyd pathologies
ZA201005770B (en) The treatment of damaged skin
HK1113089A (en) N-acetylcysteine amide (nac amide) for the treatment of diseases and conditions associated with oxidative stress
AU2009900848A0 (en) Positive Inotrope Agent, Positive Lusitrope Agent and Agent for the Treatment of Related Diseases
AU2009900265A0 (en) Treatment of diabetes and other diseases
HK1164053A (en) Thienopyridine derivatives for the treatment and prevention of dengue virus infections
GB0801511D0 (en) The treatment of ophthalmic diseases
GB0901727D0 (en) The treatment of ophthalmic diseases
HK1142097A (en) Treatment and prevention of influenza
AU2007902616A0 (en) Treatment and prevention of influenza
GB0700755D0 (en) The Treatment of ophthalmic diseases
AU2008901947A0 (en) Treatment of Ores
HK1165808A (en) Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorders
AU2007900455A0 (en) Compounds and Methods of Treatment
HK1170238A (en) Indolyl-substituted pyrazino-quinolines and their use for the treatment of cancer
AU2010903595A0 (en) Treatment and diagnosis of epigenetic disorders and conditions

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10822598

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10822598

Country of ref document: EP

Kind code of ref document: A2